Arai, S. (2018). Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationArai, S. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationArai, S. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.